In conclusion, our meta-analysis of the literature suggests that incorporating chimeric peptides, specifically designed to interact with the LRP-1, holds promise as a targeted approach for drug delivery in breast cancer treatment. The gene discussed is LRP1; the disease is breast carcinoma.